Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2770951 | 0.91 | USP2 (0.48) | CYP1A2TSHRUSP2ALDH1A1LMNA | |
| SCHEMBL8211734 | 0.90 | LMNA (0.57) | CYP1A2TSHRUSP2ALDH1A1LMNA | |
| SCHEMBL15941627 | 0.81 | USP2 (0.34) | CYP1A2TSHRUSP2ALDH1A1LMNA | |
| SCHEMBL4287905 | 0.79 | CNR2 (0.33) | CYP2D6CYP2C19 | |
| SCHEMBL25217168 | 0.76 | — | — | |
| SCHEMBL8182036 | 0.74 | LMNA (0.43) | CYP1A2TSHRUSP2ALDH1A1LMNA | |
| SCHEMBL23459103 | 0.72 | KMT2A (0.31) | ALDH1A1 | |
| SCHEMBL25353404 | 0.72 | EPHX2 (0.31) | — | |
| SCHEMBL13162528 | 0.71 | HCRTR2 (0.42) | TSHRALDH1A1 | |
| SCHEMBL99571 | 0.71 | CNR2 (0.40) | CYP1A2TSHRUSP2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357133-A1 | NANOMATERIALS COMPRISING CARBONATES | BEAM THERAPEUTICS INC. | 2023-11-09 | — | — | US | disclosed |
| EP-4262818-A1 | NANOMATERIALS COMPRISING CARBONATES | Beam Therapeutics Inc. (US) | 2023-10-25 | — | — | EP | disclosed |
| WO-2023154818-A1 | MUCOSAL ADMINISTRATION METHODS AND FORMULATIONS | MODERNATX, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023076598-A1 | LIPID AMINES | MODERNATX, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2022140239-A1 | NANOMATERIALS COMPRISING CARBONATES | BEAM THERAPEUTICS INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| EP-3655406-A1 | SUBSTITUTED PYRROLOPYRIDINE-DERIVATIVES | Bayer Pharma Aktiengesellschaft (DE) | 2020-05-27 | — | — | EP | disclosed |
| WO-2019016071-A1 | SUBSTITUTED PYRROLOPYRIDINE-DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-01-24 | — | — | WO | disclosed |
| EP-2953954-B1 | MACROCYCLIC COMPOUNDS AS HCV ENTRY INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-15 | — | — | EP | disclosed |
| US-9624245-B2 | Macrocyclic compounds as HCV entry inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-04-18 | — | — | US | disclosed |
| EP-2760872-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2016-04-13 | — | — | EP | disclosed |
| EP-2953954-A1 | MACROCYCLIC COMPOUNDS AS HCV ENTRY INHIBITORS | Bristol-Myers Squibb Company (US) | 2015-12-16 | — | — | EP | disclosed |
| WO-2014123894-A1 | MACROCYCLIC COMPOUNDS AS HCV ENTRY INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-14 | — | — | WO | disclosed |
| EP-2760872-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2014-08-06 | — | — | EP | disclosed |
| WO-2013048995-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357133-A1 | NANOMATERIALS COMPRISING CARBONATES | PHOSPHO1, CA13, SGMS2 | CYP1A2 2579/4885TSHR 4434/4885USP2 3475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.